Artificial Intelligence: Modulating BET Bromodomain Inhibitor ZEN-3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform (Adv. Therap. 6/2018)
Advanced Therapeutics - United Kingdom
doi 10.1002/adtp.201870020
Full Text
Open PDFAbstract
Available in full text
Date
October 1, 2018
Authors
Publisher
Wiley